We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

BMO Capital opined on Monday that recent reports indicating Robert F. Kennedy Jr.'s plan to remove all members of the U.S.

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Parents with children insured by Medicaid fear changes to the government program mean vaccines will no longer be covered.

In clinical trials, however, lenacapavir — which has been FDA-approved since 2022 to treat certain types of HIV infections — was found to be more effective at HIV prevention than a daily PrEP pill.